Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 2

The effects of lack of melatonin in experimental rat model of Alzheimer’s Disease: relationship with FEZ1 gene expression

Pages
217–223
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results showed that in AD made up in the deficiency of melatonin, FEZ1 levels got higher and the increases were revealed to return to normal levels with exogenous melatonin application

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Alzheimer’s Disease (AD), which is the most common reason for dementia, is an irreversible neurodegenerative brain disease.
📊
Key Findings & Data:FEZ1 is a protein expressed in the brain.
💡
Conclusion & Impact:Our results showed that in AD made up in the deficiency of melatonin, FEZ1 levels got higher and the increases were revealed to return to normal levels with exogenous melatonin application
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Alzheimer’s Disease (AD), which is the most common reason for dementia, is an irreversible neurodegenerative brain disease. FEZ1 is a protein expressed in the brain. High expressions of FEZ1 mRNA have been interpreted as an indicator of high neural plasticity for memory and learning. This study was planned to determine the effect of melatonin deficiency (pinealectomy; PnX) on AD and to reveal its association with FEZ1. 30 male rats were used in the study. The rats were divided into three as SHAM, PnX+streptozotocin (STZ) and PnX+STZ+melatonin (MLT) groups. The pineal glands of rats were surgically removed (except SHAM group) and STZ was intracerebroventricularly (icv) administrated at the first and third days. MLT (10 mg/kg/day) was intraperitoneally (ip) injected 1 h before the first STZ application and it was continued for 14 days. STZ and MLT solvents were applied to the rats in the SHAM group. At the end of the applications, Morris water maze (MWM) test was carried out the rats. At the end of MWM tests, the rats were sacrificed and their blood and hippocampus tissues were taken. FEZ1 gene expression and protein levels were determined from hippocampus tissue, while serum nonadrenaline, dopamine and serotonin levels were detected from blood samples. FEZ1 protein levels of PnX+STZ+MLT group were found to be statistically significantly lower than those of SHAM and PnX+STZ groups (p<0.05). While noradrenaline levels were found to be lower in both groups when compared with the SHAM group (p<0.05), no difference was found between the dopamine and serotonin levels of groups. Our results showed that in AD made up in the deficiency of melatonin, FEZ1 levels got higher and the increases were revealed to return to normal levels with exogenous melatonin application

🔖

Cite This Article

DEMİR, M., YILMAZ, Ü., ÇOLAK, C., ÇİĞREMİŞ, Y., ÖZYALIN, F., TEKEDERELİ, İ., KILINÇLI, A., SANDAL, S. (2017). The effects of lack of melatonin in experimental rat model of Alzheimer’s Disease: relationship with FEZ1 gene expression. Medicine Science, Cilt: 6 - Sayı: 2, 217–223. https://ajindex.com/articles/277348

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rodriguez-Perdigon M, Tordera RM, Gil-Bea FJ, Gerenu G, Ramirez MJ, Solas M. Down-regulation of glutamatergic terminals (VGLUT1) driven by Abeta in Alzheimer's disease. Hippocampus. 2016;26(10):1303-12
  2. Lee JS, Kim JY, Kim HJ, Kim JC, Lee JS, Kim N, Park MJ. Effects of combined radiofrequency field exposure on amyloid-beta-induced cytotoxicity in HT22 mouse hippocampal neurones. J Radiat Res. 2016;20 [Epub ahead of print]
  3. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72(6):789-802
  4. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta neuropathol. 2012;123(1):133-51
  5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83(13):4913-7
  6. Pickett EK, Koffie RM, Wegmann S, Henstridge CM, Herrmann AG, Colom-Cadena M, Lleo A, Kay KR, Vaught M, Soberman R, Walsh DM, Hyman BT, Spires-Jones TL. Non-Fibrillar Oligomeric Amyloid-beta within Synapses. J Alzheimers Dis. 2016;53(3):787- 800
  7. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6(1):27
  8. Loureiro JA, Rocha S, Pereira Mdo C. Charged surfactants induce a non-fibrillar aggregation pathway of amyloid-beta peptide. J Pept Sci. 2013;19(9):581-7
  9. Yang X, Sun GY, Eckert GP, Lee JC. Cellular membrane fluidity in amyloid precursor protein processing. Mol Neurobiol. 2014;50(1):119-29
  10. Zambrano N, Gianni D, Bruni P, Passaro F, Telese F, Russo T. Fe65 is not involved in the platelet-derived growth factor-induced processing of Alzheimer's amyloid precursor protein, which activates its caspase-directed cleavage. J Biol Chem. 2004;279(16):16161-9
  11. Piao Y, Kimura A, Urano S, Saito Y, Taru H, Yamamoto T, Hata S, Suzuki T. Mechanism of intramembrane cleavage of alcadeins by gamma-secretase. PloS one. 2013;8(4):e62431
  12. Kowalska A. The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease. Neurol Neurochir Pol. 2004;38(5):405-11
  13. Naslund J, Jensen M, Tjernberg LO, Thyberg J, Terenius L, Nordstedt C. The metabolic pa